China's National Medical Products Administration (NMPA) has granted emergency approval to Shanghai Fosun Long March Medical Science Co Ltd, a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co Ltd (Stock Code: 600196.SH, 02196.HK), for its self-developed novel coronavirus nucleic acid detection kit, it was reported on Thursday.
According to the company, this kit can realise qualitative detection of novel coronavirus ORF1ab, N and E gene targets and can complete the detection of 96 samples within two hours by supporting fast nucleic acid extraction instrument and extraction reagents. It is also claimed to decrease the risk of operator infection, reduce the risk of cross contamination in the laboratory, and improve detection efficiency.
The company said that it has paid close attention to the development of the epidemic since the outbreak of COVID-19, based on its perennial provision of speedy test reagents for Type A&B flu and common respiratory viruses.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib